On the mechanism of alkylphosphocholine (APC)-induced apoptosis in tumour cells

Biological Chemistry

Volumn 386, Issue 3, 2005, Pages 237-245

  Oberle, Carolin ^a   Massing, Ulrich ^b   Krug, Harald F ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bid; Caspase activation; Mitochondria; Mitochondrial membrane permeabilisation; S NC 2

Indexed keywords

1 O PHOSPHOCHOLINE 2 N ACETYL OCTADECANE; ALKYLPHOSPHOCHOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CAVEOLIN; DEATH RECEPTOR; FAS ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; LIPID RAFT; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; HUMANS; MITOCHONDRIA; PHOSPHORYLCHOLINE;

EID: 16844385041     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2005.029     Document Type: Article

References (51)

1. Abedinpour, P. and Jergil, B. (2003). Isolation of a caveolae-enriched fraction from rat lung by affinity partitioning and sucrose gradient centrifugation. Anal. Biochem. 313, 1-8.
2. Andreesen, R., Modolell, M., Oepke, G.H., Common, H., Lohr, G.W., and Munder, P.G. (1982). Studies on various parameters influencing leukemic cell destruction by alkyl-lysophospholipids. Anticancer Res. 2, 95-100.
3. Ashkenazi, A. and Dixit, V.M. (1998). Death receptors: signaling and modulation. Science 281, 1305-1308.
4. Ashkenazi, A. and Dixit, V.M. (1999). Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255-260.
5. Cifone, M.G., Roncaioli, P., De Maria, R., Camarda, G., Santoni, A., Ruberti, G., and Testi, R. (1995). Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 14, 5859-5868.
6. Clive, S., Gardiner, J., and Leonard, R.C. (1999). Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemother. Pharmacol. 44 (Suppl.), S29-S30.
7. Cremesti, A., Paris, F., Grassme, H., Holler, N., Tschopp, J., Fuks, Z., Gulbins, E., and Kolesnick, R. (2001). Ceramide enables fas to cap and kill. J. Biol. Chem. 276, 23954-23961.
8. Eibl, H. and Unger, C. (1990). Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev. 17, 233-242.
9. Ferri, K.F. and Kroemer, G. (2001). Organelle-specific initiation of cell death pathways. Nat. Cell Biol. 3, E255-E263.
10. Gajate, C. and Mollinedo, F. (2001). The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98, 3860-3863.
11. Gajate, C. and Mollinedo, F. (2002). Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab. 3, 491-525.
12. Gajate, C., Fonteriz, R.I., Cabaner, C., Alvarez-Noves, G., Alvarez-Rodriguez, Y., Modolell, M., and Mollinedo, F. (2000a). Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int. J. Cancer 85, 674-682.
13. Gajate, C., Santos-Beneit, A.M., Macho, A., Lazaro, M., Hernandez-De Rojas, A., Modolell, M., Munoz, E., and Mollinedo, F. (2000b). Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int. J. Cancer 86, 208-218.
14. Garcia, A., Cayla, X., Fleischer, A., Guergnon, J., Alvarez-Franco, C.F., Rebollo, M.P., Roncal, F., and Rebollo, A. (2003). Rafts: a simple way to control apoptosis by subcellular redistribution. Biochimie 85, 727-731.
15. Gniadecki, R. (2004). Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem. Biophys. Res. Commun. 320, 165-169.
16. Grassme, H., Schwarz, H., and Gulbins, E. (2001). Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem. Biophys. Res. Commun. 284, 1016-1030.
17. Grassme, H., Cremesti, A., Kolesnick, R., and Gulbins, E. (2003). Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 22, 5457-5470.
18. Gross, A., Yin, X.M., Wang, K., Wei, M.C., Jockel, J., Milliman, C., Erdjument-Bromage, H., Tempst, P., and Korsmeyer, S.J. (1999). Caspase cleaved BID, targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274, 1156-1163.
19. Hengartner, M.O. (2000). The biochemistry of apoptosis. Nature 407, 770-776.
20. Hilgard, P., Stekar, J., Voegeli, R., Engel, J., Schumacher, W., Eibl, H., Unger, C., and Berger, M.R. (1988). Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur. J. Cancer Clin. Oncol. 24, 1457-1461.
21. Jendrossek, V. and Handrick, R. (2003). Membrane-targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr. Med. Chem. Anticancer Agents 3, 343-353.
22. Jendrossek, V., Kugler, W., Erdlenbruch, B., Eibl, H., Lang, F., and Lakomek, M. (2001). Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations. Anticancer Res. 21, 3389-3396.
23. Jendrossek, V., Muller, I., Eibl, H., and Belka, C. (2003). Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 22, 2621-2631.
24. Juo, P., Woo, M.S., Kuo, C.J., Signorelli, P., Biemann, H.P., Hannun, Y.A., and Blenis, J. (1999). FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ. 10, 797-804.
25. Kamp, D.W., Panduri, V., Weitzman, S.A., and Chandel, N. (2002). Asbestos-induced alveolar epithelial cell apoptosis: role of mitochondrial dysfunction caused by iron-derived free radicals. Mol. Cell Biochem. 234-235, 153-160.
26. Kischkel, F.C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P.H., and Peter, M.E. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14 5579-5588.
27. Koenigsmann, M.P., Notter, M., Knauf, W.U., Papadimitriou, C.A., Oberberg, D., Reufi, B., Mucke, C., Thiel, E., and Berdel, W.E. (1996). Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on haematopoietic rescue after high-dose therapy. Bone Marrow Transplant. 18, 549-557.
28. Kotting, J., Marschner, N.W., Neumuller, W., Unger, C., and Eibl, H. (1992). Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog. Exp. Tumor Res. 34, 131-142.
29. Krammer, P.H. (2000). CD95's deadly mission in the immune system. Nature 407, 789-795.
30. Krug, H.F., Oberle, C., Matzke, A., and Massing, U. (2003). The antiproliferative alkylphospholipid S-1-O-phosphocholine-2-N acetyl-octadecane (S-NC-2) induces apoptosis in leukemia cell lines. Ann. NY Acad. Sci. 1010, 335-338.
31. Lavrik, I., Krueger, A., Schmitz, I., Baumann, S., Weyd, H., Krammer, P.H., and Kirchhoff, S. (2003). The active caspase-8 heterotetramer is formed at the CD95 DISC. Cell Death Differ. 10, 144-145.
32. Lutter, M., Perkins, G.A., and Wang, X. (2001). The pro-apoptotic Bcl-2 family member tBid localizes to mitochondrial contact sites. BMC Cell Biol. 2, 22.
33. Massing, U. and Eibl, H. (1994). Synthesis of enantiomerically pure 1-O-phosphocholine-2-O-acyl-octadecane and 1-O-phosphocholine-2-N-acyl-octadecane. Chem. Phys. Lipids 69, 105-120.
34. Matzke, A., Massing, U., and Krug, H.F (2001). Killing tumour cells by alkylphosphocholines: evidence for involvement of CD95. Eur. J. Cell Biol. 80, 1-10.
35. McGill, G. and Fisher, D.E. (1997). Apoptosis in tumorigenesis and cancer therapy. Front. Biosci. 2, 353-379.
36. Mollinedo, F., Fernandez-Luna, J.L., Gajate, C., Martin-Martin, B., Benito, A., Martinez-Dalmau, R., and Modolell, M. (1997). Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res. 57, 1320-1328.
37. Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365.
38. Oberle, C., Massing, U., and Krug, H.F. (2003). S-1-O Phosphocholine-2-N-acetyl-octadecane induces apoptosis in T-cells: involvement of receptor activation and the intrinsic apoptotic pathway. Signal Transduction 5/6, 218-231.
39. Peter, M.E. and Krammer, P.H. (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10, 26-35.
40. Quest, A.F., Leyton, L., and Parraga, M. (2004). Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease. Biochem. Cell Biol. 82, 129-144.
41. Ruiter, G.A., Zerp, S.F., Bartelink, H., van Blitterswijk, W.J., and Verheij, M. (1999). Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. 59, 2457-2463.
42. Ruiter, G.A., Verheij, M., Zerp, S.F., and van Blitterswijk, W.J. (2001). Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys. 49 415-419.
43. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., and Peter, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687.
44. Scaffidi, C., Schmitz, I., Zha, J., Korsmeyer, S.J., Krammer, P.H., and Peter, M.E. (1999). Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 274, 22532-22538.
45. Scheel-Toellner, D., Wang, K., Assi, L.K., Webb, P.R., Craddock, R.M., Salmon, M., and Lord, J.M. (2004). Clustering of death receptors in lipid rafts initiates neutrophil spontaneous apoptosis. Biochem. Soc. Trans. 32, 679-681.
46. Siegel, R.M., Chan, F.K., Chun, H.J., and Lenardo, M.J. (2000). The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1, 469-474.
47. Thornberry, N.A. and Lazebnik, Y. (1998). Caspases: enemies within. Science 281, 1312-1316.
48. Unger, C., Eibl, H., Breiser, A., von Heyden, H.W., Engel, J., Hilgard, P., Sindermann, H., Peukert, M., and Nagel, G.A. (1988). Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial. Onkologie 11, 295-296.
49. Unger, C., Damenz, W., Fleer, E.A., Kim, D.J., Breiser, A., Hilgard, P., Engel, J., Nagel, G., and Eibl, H. (1989). Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol. 28, 213-217.
50. Vogler, W.R. and Berdel, W.E. (1993). Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow. J. Hematother. 2, 93-102.
51. Zimmermann, K.C., Bonzon, C., and Green, D.R. (2001). The machinery of programmed cell death. Pharmacol. Ther. 92, 57-70.